Co-payment for certain medicinal products is based on the maximum recommended dose according to the marketing authorisation of a medicinal product in Iceland, as applicable, recognised clinical guidelines will also be used. After the change, there is no co-payment of the dose that exceeds the recommended maximum dose. The new arrangement took effect on 1 January 2026. Drug use, which is the basis for assessing whether the maximum dose has been reached, is calculated from that time. In April 2026, co-payment for the part that exceeds the recommended maximum dose will cease. If use is according to the recommended maximum dose, co-payment is obtained according to the co-payment system, but if use is above the maximum dose, co-payment is not received for the dose that is in excess

The change is in accordance with Article 6 of Regulation No. 1143/2019 on the contribution of Iceland Health to the cost of medicines, which states, among other things:

"Iceland Health is authorized to limit the contribution of Iceland Health to an individual's medication costs, which has been approved pursuant to subsection 2, paragraph 2 of Article 66 of the Pharmaceuticals Act, to a specific dosage that exceeds the recommended maximum dosage according to the marketing authorization of the medicine in this country."

[11.12.25 This news has been updated] More detailed information about the change can be found here:

[The article was republished and updated on 24.04.26]